Moderna (NASDAQ:MRNA) Stock Purchase Disclosed by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Moderna, Inc. (NASDAQ:MRNA). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Moderna stock on October 20th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.

Moderna Stock Down 7.0%

NASDAQ MRNA traded down $17.34 during trading on Thursday, reaching $231.35. 6,963,200 shares of the company’s stock traded hands, compared to its average volume of 12,594,596. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $280.80. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. The firm has a market cap of $93.61 billion, a price-to-earnings ratio of -32.58 and a beta of 1.16. The company’s 50 day simple moving average is $200.18 and its two-hundred day simple moving average is $95.52.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. During the same quarter in the prior year, the business earned ($0.51) earnings per share. Moderna’s revenue was up 29.2% on a year-over-year basis. As a group, sell-side analysts forecast that Moderna, Inc. will post -5.34 EPS for the current fiscal year.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 34,836 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider owned 74,129 shares of the company’s stock, valued at $10,374,353.55. The trade was a 4.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 197,251 shares of company stock valued at $33,875,904 over the last 90 days. Corporate insiders own 10.80% of the company’s stock.

More Moderna News

Investors following MRNA have been watching these news items:

• Neutral Sentiment: Moderna presented an oncology-led growth strategy, including work on its personalized cancer vaccine. That pipeline could become a meaningful source of future growth, but its commercial potential remains uncertain and will take time to establish. Article: Moderna’s Oncology Growth Plan
• Negative Sentiment: Investors focused on the cost of that strategy: Moderna expects about $4 billion in cash costs in 2027. The planned investment raises the stakes for its cancer programs and could prolong the path to profitability. Article: Moderna Analyst Day Spending
• Negative Sentiment: Despite the raised forecast, coverage noted that Moderna’s 2026 revenue outlook may still be below analyst expectations, fueling concern about a potential sales shortfall. That outlook, combined with elevated investment needs, appears to have outweighed the positive updates. Article: Why Moderna Stock Dropped

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on MRNA shares. Loop Capital set a $135.00 target price on Moderna in a research note on Wednesday, August 19th. Rothschild & Co Redburn downgraded Moderna from a “neutral” rating to a “sell” rating and raised their price target for the stock from $40.00 to $81.00 in a report on Thursday, September 3rd. William Blair downgraded Moderna from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 27th. TD Cowen restated a “buy” rating on shares of Moderna in a research note on Wednesday, October 21st. Finally, Singular Research upgraded shares of Moderna to a “hold” rating in a report on Wednesday, September 23rd. Six investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $113.75.

Institutional Trading of Moderna

A number of hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Moderna in the 2nd quarter worth $2,142,877,000. Theleme Partners LLP acquired a new position in Moderna during the second quarter worth $564,272,000. Merck & Co. Inc. purchased a new position in Moderna during the second quarter valued at $161,642,545. Bamco Inc. NY purchased a new position in Moderna during the second quarter valued at $139,317,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Moderna in the second quarter valued at about $119,168,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Moderna Company Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.